טוען...
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
OBJECTIVE: Inaccessibility of the inflammation compartmentalized to the central nervous system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in progressive multiple sclerosis (MS). The double blind combination of Rituximab by IntraVenous and IntraThecAl injection versus plac...
שמור ב:
| הוצא לאור ב: | Ann Clin Transl Neurol |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4774261/ https://ncbi.nlm.nih.gov/pubmed/27042677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.293 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|